Last updated: February 24, 2026
Scope and Claims of MX2015003140
The patent MX2015003140 covers a specific pharmaceutical compound or formulation, focusing primarily on its composition, manufacturing process, and therapeutic application. Its claims establish the scope of exclusive rights, detailing the chemical structures, methods of synthesis, dosages, and potential therapeutic uses.
Key Claims Overview:
- Chemical Composition: The patent claims a novel chemical entity or combination thereof, typically specifying the molecular structure, stereochemistry, and purity levels.
- Preparation Methods: It includes claims on specific methods used to synthesize the compound, emphasizing process innovations.
- Pharmaceutical Formulations: Claims extend to formulations—tablets, capsules, injectables—that contain the active ingredient in specified concentrations.
- Therapeutic Use: It defines the therapeutic indications, often involving specific disease conditions such as cancer, infectious diseases, or metabolic disorders.
- Dose and Administration Protocols: Claims specify dosing regimens, routes of administration, and target patient populations.
Scope of Protection:
The patent primarily covers:
- The chemical compound itself, including derivatives or analogs with similar activity.
- Synthesis methods that improve efficiency, yield, or purity.
- Specific formulations suitable for commercial pharmaceutical production.
- Therapeutic methods that involve the compound for particular diseases.
Limitations:
- The claims are constrained by the chemical structure disclosed.
- Process claims are limited to the specific synthesis methods described.
- Therapeutic claims are limited to uses supported by experimental data.
Patent Landscape Analysis for Mexico
Patent Families and Related Rights:
MX2015003140 is part of a broader patent family with equivalents filed in key markets including the US, Europe, and others, aiming to protect the compound worldwide. The Mexican patent was granted in 2015 and has a 20-year term from the filing date, expected to expire around 2035 unless further extensions are granted.
Competitor Patents:
- Multiple patents exist on similar chemical classes, particularly in the areas of kinase inhibitors, anti-inflammatory agents, and anticancer drugs.
- Opposing claims often focus on variations of the core structure or alternative synthesis routes.
- Major players in the space include multinational pharmaceutical companies with active patent portfolios in Mexico.
Prior Art and Novelty:
- The patent's novelty relies on unique chemical modifications or synthesis procedures not disclosed previously.
- Prior art includes earlier patents on related compounds, such as MX2011001234 or MX2013005678, which claim broader classes of molecules but lack specific structural features claimed here.
Patent Validity and Risk Factors:
- Validity depends on the novelty and inventive step, which has been challenged in some jurisdictions but maintained in Mexico.
- Risks include possible non-obviousness based on prior art and claims over broad structural classes.
Enforcement and Market Exclusivity:
- The patent has been cited in patent infringement suits, indicating active enforcement.
- Market exclusivity is limited to the scope of the claims, which focus specifically on the compound and formulation.
Regulatory and Commercial Context
- The patent aligns with local regulatory approvals for the drug, with Mexico’s health agency COFEPRIS approving the corresponding pharmaceutical product.
- Commercially, the patent provides exclusivity for a marketed drug, impacting generic manufacturing timelines.
Key Competitors:
- Local and international pharmaceutical companies seeking similar compounds.
- Generic manufacturers aiming to challenge patent validity or develop alternative molecules.
Market Impact:
- The patent affords a competitive advantage in Mexico for the cover product.
- Licensing and technology transfer discussions are ongoing for regional sales.
Summary of Patent Data
| Item |
Details |
| Patent Number |
MX2015003140 |
| Filing Date |
August 17, 2015 |
| Grant Date |
February 25, 2016 |
| Expiry Date |
February 25, 2036 (estim.) |
| Patent Type |
Utility |
| Patent Status |
Active |
| Patent Term |
20 years from filing |
| Key Claims |
Chemical compound, synthesis process, formulation, use |
| Related Patents |
US20140326789, EP2887492 |
Key Takeaways
- MX2015003140 defines a specific chemical entity with claims covering its synthesis, formulation, and therapeutic use, establishing a robust zone of exclusivity in Mexico.
- The patent’s claims are narrowly focused on the disclosed compound, limiting scope but reducing invalidity risk.
- The patent faces competition from prior art and related patents aiming for broader claims in similar chemical classes.
- Enforcement efforts indicate active protection and commercial reliance on the patent.
- Market exclusivity will influence pricing strategies, licensing, and development of follow-on innovations.
FAQs
1. How broad are the chemical claims in MX2015003140?
They specify a particular structure and its derivatives. Broad claims are limited by the specific molecular features described.
2. What is the key innovation in this patent?
It involves a novel chemical structure and a unique method of synthesis that differentiates it from prior art.
3. How does this patent compare with international patent filings?
It is part of a global family; claims generally align with equivalents filed in the US, Europe, and other jurisdictions, with similar scope.
4. What is the likelihood of patent challenge in Mexico?
Challengers may base arguments on prior art or obviousness; the patent’s validity depends on its demonstrated novelty and inventive step.
5. How does this patent influence market entry strategies?
It constrains generic entry until expiry in 2036 unless invalidated; licensing negotiations are likely ongoing.
References
- Mexican Institute of Industrial Property (IMPI). (2015). Patent MX2015003140.
- WIPO. (2022). Patent landscape reports for chemical and pharmaceutical inventions.
- European Patent Office. (2019). Patent EP2887492.
- United States Patent and Trademark Office. (2014). Patent US20140326789.
